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IV REPORT OF THE SCIENTIFIC COMMITTEE FOR FOOD 
ON SWEETENERS 
(Opinion expressed 14 September 1984) 
TERMS OF REFERENCE 
To review the safety in use of certain sweeteners. 
BACKGROUND 
The Commission is presently developing proposals for legislation on a number of categories 
of additives for which, as yet, there are no Community rules. The Corrmittee was asked by 
the Commission to assist by giving an opinion on the safety of the additives included in 
the Commission's review. Sweeteners are among the additives included in the review. 
Sweeteners fulfil several special roles in the diet. They may be food additives, a 
replacement for sucrose, or tabletop sweeteners, thus complicating their evaluation in 
terms of safety. Furthermore, the legislative control of sweeteners and their permitted 
uses in particular foods vary considerably within the Community. Thus it was decided to 
prepare a separate report on sweeteners, to be published in advance of the general review 
on additives not yet assessed by the Corrmittee. Added impetus for an early report on 
sweeteners by the Committee has derived from the avai Lability of a large body of new 
information on the safety of substances in this class. 
The class of sweeteners included in the review comprises substances ranging from products 
that could be considered almost as foodstuffs in their own right to substances which due to 
their "intense" sweetness produce their required effect in minute quantities. It is 
generally accepted that alternative non-carbohydrate sweeteners fall conveniently into two 
types based on their relative sweetness compared to sucrose. Those substances with a 
sweetness "value" similar to sucrose may be called "bulk" sweeteners. 
The Committee was advised that there is interest in the following bulk sweeteners: 
Isomalt 
Lactitol 
Maltitol and maltitol-based products (hydrogenated glucose syrups) 
Mamitol 
Sorbitol 
Volemitol 
Xylitol. 
Similarly, interest has been expressed in the following intense sweeteners: 
Acesulfame potassium 
Aspartame 
Cyclamic acid and its calcium and sodium salts 
Glycyrrhizin 
Miraculin 
Monellin 
Neohesperidine dihydrochalcone 
1 -Saccharin and its calcium, sodium and potassium salts 
Stevioside 
Thaumatin. 
A summary of the evaluations is given in Amex 1. Individual assessments are given in 
Annex 2. 
Societal demands for innovations and the changing pattern of lifestyle has stimulated the 
food industry to provide foods different from traditional products. Modified food 
ingredients, e.g. certain polyol-based sweeteners, play an important role in the 
development of such products. 
In the Committee's opinion these developments require to be kept under review, bearing in 
mind their potential nutritional implications and the effect of bulking agents, fibre, 
modified starches, etc. on the gut microflora. These questions have not been addressed in 
detail in this report but should be researched in the future. The Committee would like to 
review the state of knowledge in three years. 
In considering the safety of sweeteners the Committee has also taken some account of the 
advantages to the consumer from the availability of sweeteners other than sugar. Some 
sweeteners have other technological functions. The Committee has evaluated these 
substances only in the context of their use as sweeteners. 
NUTRITIONAL CONSIDERATIONS 
Sucrose has been a sweetener for centuries but sugar consumption has increased considerably 
since the beginning of the 20th century, particularly in the north of Europe and in Anglo-
Saxon countries (FAO, 1980). Although the proportion of energy supplied by total ingested 
carbohydrates decreases generally with rising income, there has been a sharp rise in the 
portion of energy supplied by sucrose. 
Sucrose plays a role not only as a source of energy. It increases insulin demand and is 
an important factor in the aetiology of dental caries, but whether it is the major one 
remains controversial. In the opinion of many nutritional experts, some control of sugar 
consumption is indicated. This is essential for diabetics but applies also to individuals 
whose body weight is excessive, and is of importance for the dental health of the general 
population. 
If it is desirable to reduce sugar consumption, several approaches are possible. Some 
nutritionists think that sustained educational efforts might alter eventually the dietary 
preferences of the population in relation to sweet foods. Foods and beverages simply with 
reduced sucrose content might therefore become more acceptable to the general consumer. 
Non-carbohydrate sweeteners provide an alternative. Among these, polyols have 
approximately the same heat of combustion but are not absorbed nor metabolised to the same 
extent as sucrose, and thus their bioavailable energy is less than that of sucrose for most 
of them. Intense sweeteners offer technological advantages in ordinary foods and in foods for 
special nutrition purposes, especially low-energy foods. Some of these sweeteners may be 
a source of calories, but at the technologically effective dose, none of the intense 
sweeteners will make a significant contribution to the energy value of the food in which 
they were to be incorporated as the levels of use are so low. 
PATHOPHYSIOLOGICAL CONSIDERATIONS 
On the available evidence none of the bulk sweeteners can be regarded as non-cariogenic. 
If a partially-fermentable sweet substance is substituted for sucrose or other fermentable 
carbohydrate, significant reductions in the incidence of dental caries might reasonably be 
expected. Such an effect is also achievable with intense sweeteners. On the basis of 
the available information, it is clear that the polyols resist fermentation by oral 
bacteria to various degrees. Studies made with animals and human volunteers provide 
support for the link between norrfermentability and norrcariogenicity. Four bulk 
sweeteners, namely hydrogenated glucose syrup, isomalt, sorbitol and xylitol have proved to 
be less cariogenic than sucrose in both animal and human experiments. 
Some bulk sweeteners cause laxation and flatulence. The general nature of the laxative 
effect, sometimes known clinically as "osmotic diarrhoea", indicates that the condition 
results from osmosis across the intestinal wall owing to the presence in the lumen of 
unabsorbed bulk sweetener and its metabolites. The amounts of the various sweeteners 
required to cause laxation depends upon the sweetener, whether the dose is spread over a 
number of meals or consumed all at once, whether the person or animal receiving the dose is 
fasting or not, and on individual differences in susceptibility to the laxative effect of 
these sweeteners. For example, young children, 2-3 years of age, tend to be more 
susceptible than children of 5-6 years of age to the same dose calculated on a g/kg bw 
basis. Moreover, the susceptibility of individuals to the laxative effect varies 
considerably as shown by human studies, in which sensitive individuals experience an effect 
at intakes of 10 g, while others can tolerate 90 g or more without adverse effects. The 
phenomenon of adaptation to the laxative effect of bulk substances has also been observed 
in animals and man. On the available evidence a consumption of the order of 20 g of 
polyols per day is unlikely to cause any undesirable laxative symptoms. 
The Committee recommends that control be exercised to limit the consumption of polyol-
containing sweeteners from all sources to levels below those at which they induce 
diarrhoea. The Committee is also of the opinion that these substances should not be used 
in foods specially prepared for infants and young children (up to 3 years of age). 
The problems associated with the way in which consumers are to be informed require further 
study by the appropriate authorities. The medical profession should be aware that 
excessive ingestion of polyol-based sweeteners may cause such undesirable effects. 
Diabetics represent a population group which may be particularly exposed to polyol 
sweeteners. 
- 3 -TECHNOLOGICAL CONSIDERATIONS 
(a) General considerations 
Sweeteners also have technological functions such as water retention or provision of bulk. 
Sucrose fulfils all these three functions when added to food. The alternative sweeteners 
all provide sweetness but some may have other properties which can be harnessed to perform 
additional functions in food. Other alternative sweeteners, weight for weight, are 
hundreds or even thousands of times as sweet as sucrose. Consequently, at the dilutions 
these substances must be used in food to avoid excessive sweetness, any other functions 
which they may perform are lost. 
Relative sweetness is subjective; it is dependent upon a number of factors. The relative 
sweetness of an intense sweetener decreases as its concentration in food is increased. It 
is also affected by temperature and by other substances consumed at the same time. 
Consequently, when determined by comparisons between aqueous solutions of sucrose and 
aqueous solutions of the substance, it can only be used as a rough guide to the likely 
sweetness of the substance in food. It provides, however, a useful comparative guide 
under well-defined conditions. 
Alternative sweetener Approximate sweetness 
(sucrose = 1) 
Acesulfame K 200 
Aspartame 200 
Cyclámate 30 
Dihydrochalcones 300-2 000 
Glycyrrhizin 50-100 
Mamitol 0.7 
Monellin 1 500-2 000 
Saccharin 300 
Sorbitol 0.54-0.7 
Stevioside 300 
Thaumatin 2 000-3 000 
Xylitol 1 
(O'Brien and Gelardi, 1981). 
(b) Bulk sweeteiers 
Some bulk sweeteners have a negative heat of solution. This property means that they 
require heat for dissolution which is obtained from their surroundings, resulting in a 
cooling effect. When dissolved in the mouth a "mouth-cooling effect" is generated. 
Xylitol, sorbitol and mamitol exhibit this property to different degrees. Bulk 
sweeteners are also used because of their action as humectants, to reduce caramelization, 
and to provide body and mouth feel in soft drinks. In certain ice-creams, bulk sweeteners 
may replace sucrose because of their technological advantage in preventing the development 
of a gritty texture from crystallization at low storage temperatures. 
- 4 -(c) Intense sweeteners 
Only low levels of the intense sweeteners are necessary to provide the desired sweetness in 
food. They make no significant contribution to the bulk of the food. 
In a way similar to the bulk sweeteners, intense sweeteners can be used in frozen food as a 
partial or total replacement for sucrose to overcome certain problems associated with high 
carbohydrate concentrations. Such food is difficult to freeze because of the freezing 
point depression of water and intense sweeteners are a useful alternative to high 
carbohydrate levels for these foods. 
By allowing the carbohydrate content to be reduced, intense sweeteners can improve the 
texture of certain foods. For example, the mouth feel of soft drink requiring a high 
degree of sweetness can be made more acceptable by using intense sweeteners to replace some 
sucrose. In addition, water-ices containing high levels of sucrose tend to be sticky and 
suffer from surface crystallization. This may be overcome by intense sweeteners partially 
replacing sucrose. Certain concentrated soft drinks require intense sweeteners to 
supplement their sweetness and maintain the cloudy nature of the product. Lowering the 
density of the solution by partial replacement of the sucrose overcomes the tendency for 
separation of some components of the drink during storage. 
TOXICOLOGICAL CONSIDERATIONS 
Special considerations relating to polyols 
Polyol sweeteners are prepared by hydrogénation of carbohydrates. Their comparatively 
high level of incorporation in prepared foods prevents their incorporation at 100-fold or 
higher levels in the diet of test animals. The dietary imbalance produced by feeding 
large doses of polyols to experimental animals is associated with physiological and 
metabolic disturbances including effects on calcium uptake and excretion. The renal 
pelvic nephrocalcinosis, adrenal medullary hyperplasia and phaeochromocytomata observed in 
these studies may be secondary to such disturbances and the Committee considered these 
findings to be of doubtful relevance to the evaluation of the safety to man of these 
compounds. 
The Committee recognizes the difficulties which may arise from testing modified food 
ingredients in the same manner as food additives in animal feeding studies. Inclusion of 
inherently non-toxic substances at high dietary levels in an attempt to demonstrate any 
potential toxic effect and establish a dose-response relationship, may result in non-
specific effects due to dietary imbalance, while failing to achieve the 100-fold higher 
experimental dietary level compared with likely human intake, necessary for establishing an 
ADI with a safety factor of 100, because of the relatively high levels (1% or more) of 
incorporation of these substances into human food. In the Committee's opinion it would be 
inappropriate to establish an ADI for polyols. 
The Committee considered it similarly inappropriate to establish an ADI for maltitol and 
maltitol-based sweeteners (sometimes known as hydrogenated glucose syrups) composed 
essentially of maltitol, sorbitol and glucose. The commercial products for which 
specifications are available vary from liquid syrups to crystalline solids containing 55% 
to 95% maltitol, 5% to 20% maltotriitol, φ to 8% sorbitol and hydrogenated tri- to 
- 5 -heptasaccharides and higher polysaccharides. The Committee would wish to evaluate any 
maltitol-based products containing individual polyols or other by-products not found in the 
products assessed in this report. 
In accepting the continued use of polyol-based sweeteners the Committee emphasized that 
this should not be interpreted as meaning the acceptance of unlimited use in all foods at 
any technological level but that the laxative effects should be borne in mind. 
6 -ANNEX 1 
Acesulfame K 
Aspartame** 
(DKP ADI 
Cyclámate 
(acid, calcium and 
sodium salts) 
Glycyrrhizin 
Isomalt 
Lactitol 
Maltitol 
(and maltitol-based 
products) 
Mamitol 
Miraculin 
Monellin 
Neohesperidine 
dihydrochalcone 
Saccharin 
(sodium, potassium 
and calcium salts) 
Sorbitol 
Stevioside 
Thaumatin 
Volemitol 
Xylitol 
SUPMARY OF EVALUATIONS OF SWEETENERS 
ADI 
ADI 
0-7.5 mg/kg bw) 
Temporary ADI 
Not toxicológically acceptable 
Acceptable* 
Acceptable* 
Acceptable* 
Acceptable* 
Not toxicológicaIly acceptable 
Not toxicologically acceptable 
Not toxi cologically acceptable 
Temporary ADI 
Acceptable* 
Not toxicologically acceptable 
Temporarily acceptable 
Not toxicologically acceptable 
Acceptable* 
0-9 mg/kg bw 
0-40 mg/kg bw 
0-11 mg/kg bw 
(expressed as 
cyclamic acid) 
0-2.5 mg/kg 
*Laxation may be observed at high intakes. Consumption of the order of 20 g/person/day 
of polyols is unlikely to cause undesirable laxative symptoms. 
**It is essential that sufferers from clinical phenylketonuria should be informed that 
this sweetener may be a source of phenylalanine when ingested. 
- 7 -ANNEX 2 
ASSESSMENT OF INDIVIDUAL SWEETENERS 
These assessments are arranged in alphabetical order for ease of reference. 
Acesulfame potassium (Acesulfame K) 
This artificial sweetener is the potassium salt of 3,4-dihydro-6-methyl-2,2,4-trioxo-
1,2,Lambda,3-oxathi azin-3-ide. 
The Corrmittee was provided with extensive toxicological data including metabolic, long-
term, reproduction and teratology studies. The long-term studies in the rat and mouse did 
not show any dose-related increase in specific tumours nor any treatment-related 
pathological changes of significance. The compound was not genotoxic in several in vitro 
and in vivo mutagenicity studies and does not bind covalently to DNA. Acesulfame K does 
not interact with model food constituents. 
In aqueous solutions, hydrolytic decomposition occurs only after prolonged storage under 
extreme conditions of temperature and pH which are not likely to occur under normal 
conditions of use. Acetoacetamide and its N-sulphonic acid are then found as 
decomposition products in the acid range. Acetoacetamide has been examined for acute 
toxicity and for mutagenicity in in vitro tests only. No data are available on the 
toxicology of the N-sulphonic acid of acetoacetamide. 
The highest level tested in rats and dogs was 3% in the diet and may be considered as the 
no-adverse-effect level, equivalent to 1 500 mg/kg bw in the rat or 900 mg/kg in the dog. 
The Committee therefore established an ADI of 0-9 mg/kg bw based on the data from the dog, 
the most sensitive species. 
Aspartame 
The chemical name of this artifical sweetener is (3s)-3-amino-N/(alpha s)-alpha-
methoxycarbonyl-phenethyl/ succinamic acid. Structurally it is N-L-alpha-aspartyl-L-
phenylalanine methyl ester. 
A very large amant of toxicological data covering acute, subchronic, long-term, 
reproduction, metabolic and mutagenicity studies were evaluated, including the 
investigation of neurobehavioural effects. The Corrmittee also reviewed the extensive 
stability data provided as well as metabolic, acute, long-term and mutagenicity studies on 
the conversion product of aspartame 5-benzyl-3,6-dioxo-2-piperazine-acetic acid 
(diketopiperazine DKP). This substance is found in aspartame-containing beverages stored 
at elevated temperatures. The Committee's critical review of the long-term studies 
established that the scattered findings of significant deviations from control values 
showed no consistent relationship to treatment, sex of animals or histopathology, so that 
4 000 mg/kg bw could be considered as a no-adverse-effect level for these studies. 
- 8 -The muItigeneratim reproduction and teratogenicity studies showed consistent adverse 
effects on the weight of progeny, both at weaning and at terminal examination, at the 
highest dose levels tested. 
The Committee reviewed additional information on the multigeneration reproduction and 
teratogenicity studies, including recalculations of the actual intake by the offsprings, 
which suggested the consumption by the pups of levels higher than which would follow from 
the composition of the test diets. The Corrmittee noted the observed growth depression in 
the progeny was marginal and related to a decrease in food consumption caused by a high 
intake of phenylalanine. In the light of these findings the Committee concluded that 
4 000 mg/kg bw could be considered as the no-adverse-effect level also in these studies. 
The Committee also reviewed the recent evidence on the effects of aspartame in combination 
with refined carbohydrates on behaviour and mood. It concluded that the data provided no 
evidence that the occasional transient changes in blood amino acid levels, following 
simultaneous ingestim of aspartame and glucose, could produce changes in neutrotransmitter 
levels which might affect mood or behaviour. 
The Committee saw no reason for cmcem over the amounts of methanol likely to be produced 
by the metabolism of aspartame when compared with those present naturally in food. 
The Committee also considered the effects of the phenylalanine contribution, following 
consumption of aspartame, m individuals heterozygous for phenylketonuria (PKU) and m 
individuals with variants of PKU causing benign hyperphenylalaninaemia. The blood levels 
of phenylalanine in these individuals were raised only slightly and none of them showed any 
neurological or other clinical abnormal findings, thus supporting the view that large 
intakes of aspartame in the diet would not cause any untoward effects in these genotypes. 
Foetal effects from excessive maternal aspartame consumption by pregnant women heterozygous 
for PKU were not likely in view of the available data m phenylalanine levels in maternal 
blood. It is however essential that sufferers from clinical PKU should be informed that 
this sweetener may be a source of phenylalanine when ingested. 
The Committee therefore established an ADI of 0-40 mg/kg bw for aspartame and an ADI of 
0-7.5 mg/kg bw for DKP. 
Cyclamic acid and its sodium salts 
The systematic chemical name of cyclamic acid is cyclohexylsulphamic acid. 
Its microbial metabolite is cyclohexylamine, chemically cyclohexanamine. 
The Committee reviewed an extensive collection of toxicological studies m cyclamates, 
cyclohexylamine and dicyclohexylamine. These covered all aspects ranging from metabolism 
to long-term carcinogenicity and reproductive function studies. They also included recent 
studies m cyclohexylamine, a metabolite of eye lámate produced by the gastro-intestinal 
microbial flora in some individuals, concerned with its toxic effects on the testis and m 
- 9 -reproduction in the rat as well as with its embryotoxic effects in mice. The recent 
long-term studies have resolved the question of carcinogenicity raised by the earlier 
long-term study. 
The precise mechanism of the testicular damage in rats is still unknown but recent 
metabolic studies suggest that the rat metabolises cyclohexylamine differently from man and 
mouse and that the testicular changes observed in the rat may be related to the particular 
metabolites in this species. Further work m these aspects is in progress. The degree 
of absorption of eyelámate from the gut appears to be up to 37%. Of the unabsorbed 
cyclamate, some 30% may be converted to cyclohexylamine but the proportion of human 
converters is small. A few individuals may convert up to higher percentages, but the 
safety factor allows for particularly sensitive subgroups of the population. A very 
carefully executed 90-day feeding study of cyclohexylamine in rats produced a no-adverse-
effect level of 100 mg/kg bw with respect to testicular damage as parameter. Although 
there was a decrease in bodyweight at 50 mg/kg bw, the mean percentage decrease was only 
significant at the next highest dose (200 mg/kg bw). The mly available long-term feeding 
study with cyclohexylamine in the rat suggested 30 mg/kg bw as NEL for testicular damage, 
but the scoring system for this effect was less comprehensive. 
In view of the existing areas of uncertainty relating to the relevance for man of the 
testicular damage found in rats fed cyclohexylamine, the Committee decided to base its 
assessment m the NEL of 100 mg/kg bw in the recent extensive 90-xlay study. The Committee 
felt that there was an adequate additional safety margin in the estimation of the 
conversion rate of cyclamate to cyclohexylamine in man to allow for the use of the usual 
100-fold safety factor and to establish a temporary ADI of 0-11 mg/kg bw, expressed as 
cyclamic acid, for cyclamic acid and its salts. The Corrmittee wishes to review the 
situation when the results of the further investigations in progress have become available. 
Glycyrrhizin 
Most commercially available liquorice is an extract prepared from the roots and rhizomes of 
glycyrhiza glabra L. Glycyrrhizin is an important biologically active constituent of 
liquorice. It is a saponine in which the aglycone, glycyrrhetic acid, is linked to B, 
B'-glucuronidoglucuronic acid. Glycyrrhetic acid is 3-B-hydroxy-11^oxoolearr12-en-30-oic 
acid. 
The Committee was informed m the use of this material as a flavouring agent and sweetener. 
The Committee reviewed studies m the pharmacological and steroidal effects, m the effects 
of acute, subacute and subchronic administration in laboratory animals as well as m 
teratology, metabolism and mutagenicity. It also considered a large number of clinical 
reports following therapeutic use. The animal data were largely concerned with resolving 
the medical problems arising from excessive ingestim of liquorice preparations. The 
available data were inadequate for a toxicological evaluation of the substance as a 
sweetener but the findings from clinical toxicology revealed the possible need to restrict 
the consumption of liquorice. The Corrmittee was informed of new studies now in progress 
and wished to be provided with the results. Meanwhile the Committee is unable to endorse 
its use as a sweetener and suggests a further assessment of the total usage. 
10 Isomalt 
This bulk sweetener is an equimolecular mixture of 6-0-alpha-D-glucopyranosyl-D-glucitol 
and 1-0-alpha-D-glucopyranosyl-D-mamitol. 
The Committee reviewed the available information which included acute and subchronic 
studies, studies m metabolism in various species including man, studies m the effect m 
the gut flora and absorption of various nutrients. A lifespan study in rats with in utero 
exposure, a carcinogenicity study in mice, a muLtigeneratim reproduction study and 
teratogenicity studies were also available for evaluation. Mutagenicity was studied only 
in a Salmonella reverse mutation test. No carcinogenicity was demonstrated in several 
studies. 
No laxative effects were noted in man at 10-20 g/day. The material is incompletely 
hydrolysed in the small intestine to glucose, sorbitol and mamitol. Further metabolism 
by the microbial flora of the large gut results in complete disappearance of the sweetener 
from the faeces. High doses fed over lifespan result in caecal enlargement and renal 
pelvic nephrocalcinosis, effects also observed with other polyols (see "Pathophysiological 
Considerations"). The Committee did not consider it appropriate to establish an ADI for 
this bulk sweetener but considered its use acceptable provided the limitations due to the 
laxative action were kept in mind. 
Lactitol 
This substance is 4-0-beta-D-galactopyranosyl-D-glucitol. It is produced by the catalytic 
hydrogénation of lactose. 
The Committee was provided with the results of acute, subchronic, metabolic, 
muLtigeneratim reproduction, teratology and long-term carcinogenicity studies in several 
species including mice, rats and dogs. The results of a SalmoneIla/microsóme reverse 
mutation test and an in vitro test m human lymphocytes, of some cariogenic studies, and of 
tolerance studies in man were also available. Lactitol is metabolised to galactose and 
sorbitol, partly in the upper intestinal tract, and also by the microbial flora of the 
large intestine. The implications of the observed effects on the kidneys and adrenals are 
discussed under "Toxicological Cmsi derati ms". Human studies showed that lactitol was 
hydrolysed at a slow rate and caused diarrhoea at an intake of about 50 g/day. The 
Corrmittee did not consider it appropriate to establish an ADI for lactitol, but considered 
its use acceptable provided the limitations due to its laxative actim were kept in mind. 
11 -Maltitol and maltitol-based products 
The Corrmittee was informed that the commercially available products are mixtures of 
substances obtained from food grade raw materials following enzymatic hydrolysis to high-
maltose-cmtaining glucose syrups and subsequent catalytic hydrogénation to reduce all free 
aldehyde groups. The commercial products vary from liquid syrups to crystalline solids, 
containing from about 50% maltitol (4-0-alpha-D-glucopyranosyl-D-glucitol) and hydrogenated 
tri- to heptasaccharides and higher polysaccharides. 
The range of minor components in the products evaluated is similar. 
The Corrmittee considered a large number of studies, the bulk of the data having been
 : 
obtained m a product containing about 55% of maltitol. Other data related to products 
with a maltitol content between 60 and 95%. The studies referring to the product with 55% 
maltitol were adequate and comprised acute toxicity, subchronic toxicity in two species, a 
large number of mutagenicity tests, metabolic investigations and several clinical tolerance 
studies. The studies referring to products with a maltitol content ranging from about 60 
to 95% covered acute and subchronic toxicity, carcinogenicity, multigeneratim 
reproduction, teratogenicity, metabolism, mutagenicity, clinical tolerance in man and 
cariogeni city. However, many of these latter studies were inadequate in terms of modem 
toxicological requirements. The mly studies on pure maltitol available to the Committee 
were studies m the metabolism of radiolabelled maltitol in the rat and man. 
The metabolic studies indicated that the maltitol component was slowly but completely 
metabolised into glucose and sorbitol in rats and man, particularly by the intestinal 
flora. The cmsiderable data base on sorbitol was also used by the Corrmittee for the 
evaluation of these products. A multigeneratim reproduction study without a 
teratological component has been performed mly with the low maltitol product but this 
study did not conform to present-day protocols. An adequate teratology study was carried 
out m the high maltitol product. The available mutagenicity studies m several high 
maltitol products showed no genotoxic potential. The existing human tolerance studies 
showed a laxative effect at intake levels of 30-50 g/day. 
The Corrmittee considered it inappropriate to establish an ADI for these products but 
considers the continued use of maltitol and maltitol-based products acceptable provided the 
limitations due to their laxative action were kept in mind. The Corrmittee did not require 
a long-term study m these compounds in view of the metabolic fate and the fact that long-
term studies m the metabolite sorbitol are already available but draws attention to its 
comments m modified food ingredients (under "Background"). 
Mamitol 
This polyol is a 1,2,3,4,5,6-hexanehexol. It is prepared by the reduction of glucose. 
The Committee reviewed studies m the metabolism in man and rats, m acute toxicity, 
limited studies on subchronic toxicity, several long-term feeding/carcinogenicity studies 
in rats and mice, a teratology study and the results of several mutagenicity tests. No 
multigeneratim-reproductim study was available. Data m human tolerance were also 
considered. This polyol is poorly absorbed and cmsiderable clinical experience exists in 
12 man. Laxative effects have been reported with doses as low as 10-20 g. The implications 
of the observed effects m adrenals and kidneys are discussed under "Toxicological 
Considerations". The Corrmittee considered it inappropriate to establish an ADI, but has 
no objectim to the continued use of this sweetener provided the limitations due to its 
laxative action are kept in mind. 
Miraculin 
This substance is a glycoprotein of uncertain composition extracted from the West African 
miracle fruit (Synsepalum dulcificum). It is a taste modifier that makes acid foods taste 
sweet, if a drop is chewed prior to eating. The sweet taste may last up to two hours after 
ingestim. 
The Corrmittee was not provided with the full data nor was the identity of the substance 
tested clarified. The Corrmittee was therefore not able to assess the safety of this 
substance. 
Monellin 
This protein comprises two non-identical polypeptide chains containing a total of about 90 
amino acids. It is present in the West African serendipity berry (Dioscoreophyllum 
curiminsii) from which it is extracted by a complex process. No toxicological data were 
available to the Corrmittee m which to base an assessment. 
Neohesperidine dihydrochaLeone 
This compound is a flavanone glucoside prepared from naringin by various chemical 
processes. It is a member of the dihydrochalcmes, which are sweeteners derived from the 
bioflavonoids of citrus fruits and which all share the same basic chemical structure as the 
component responsible for sweetness. 
The Committee reviewed studies m the metabolism, acute toxicity, subchronic toxicity, 
multigeneratim reproduction, teratogenicity, and chronic toxicity. Several in vitro and 
in vivo mutagenicity studies were also available. Neither of the chronic toxicity studies 
in rats and dogs established a clear no-adverse-effect level. The Committee was therefore 
unable to assess the safety of this sweetener until a no-adverse-effect level was 
established in an adequately conducted 90-day study in the rat. 
- 13 -Saccharin and its sodium, potassium and calcium salts 
This sweetener is 1,2 benzisothiazol-3(2H)-one-1,1-dioxide. 
The Corrmittee reviewed a large number of studies which had become available since its first 
report m this substance in 1977. A temporary ADI of 0-2.5 mg/kg/day was then established 
by the Committee but it also recommended that the situation should be kept under review and 
that this ADI should be reassessed after ongoing studies had bem evaluated. Many of 
these studies, which are now available, were concerned with the promotional effects of 
saccharin m bladder carcinoma, including human epidemiological data and an extensive 
long-term feeding study in rats. No further long-term studies were done in the mouse. 
Saccharin is not genotoxic in mutagenicity studies and is not metabolised by man. The 
recent long-term study in male rats showed that exposure from birth results in a dose-
dependent production of bladder tumours. The difference in the incidence of tumours in 
the 1% test group compared to cmtrols was not statistically significant, so that the 1% 
dietary level appears to be a possible no-effect level. 
In promotional studies m bladder tumours, no statistically significant difference was 
observed at the 0.04% level under the conditions of the tests, but their relevance for man 
is not known. Recent studies in man have shown that the effect of saccharin m the 
production of indican, a promoter for bladder tumours, by the intestinal bacteria may 
differ quantitatively for the rat and man, making the findings in rats of questionable 
significance for man. Epidemiological studies have also not established any evidence that 
bladder cancer in man is associated with saccharin intake; this is the mly association 
examined. 
The Corrmittee therefore decided to maintain the temporary ADI of 0-2.5 mg/kg bw/day, 
allocated in 1977, but that the situation should be kept under review and that the ADI 
should be reassessed after the Committee had evaluated the results of ongoing studies m: 
(a) the report to be published m the outcome of the two-generation study in hamsters 
recently completed, 
(b) the mechanism of the effect of saccharin m the bladder in the male rat, 
(c) the comparability of the rat and human bladder in relatim to differences in metabolism 
and local effects. 
14 -Sorbitol 
This sweetener is a 1,2,3,4,5,6-hexanehexol. 
It is present in a wide variety of fruits, berries and plants. It is produced 
commercially by hydrogenating dextrose. 
The Corrmittee considered the numerous available studies which included metabolic, acute 
subchronic, two chronic toxicity studies in rats and one in dogs, a three generatim 
reproduction and teratogenicity study. The Corrmittee also reviewed several mutagenicity 
studies. Extensive human data exist m the use of sorbitol in foods for special 
nutritional purposes for diabetics, and m human tolerance studies. Laxative effects were 
noted at intake levels above 50 g/day. The comments m the effects of polyols m calcium 
metabolism and m laxatim apply equally to sorbitol. The Corrmittee did not cmsider it 
appropriate to establish an ADI for sorbitol but had no objectim to the continued use of 
this sweetener provided the limitations due to its laxative actim were kept in mind. 
Stevioside 
This sweetener is one of the glycosides isolated from the leaves of Stevia rebaudiana 
(Bert.) Hemsl. It is an ester of steviol, beta-D-glucosyl and beta-D-sophorosyl groups. 
The Corrmittee reviewed the available studies m the pharmacological activity of crude 
extracts of leaves of Stevia rebaudiana, acute and subchronic toxicity and m mutagenicity. 
A chrmic toxicity combined with carcinogenicity study is in progress. The available 
reproduction study did not indicate any effect m fertility but mly one generation was 
studied. Little data are available on metabolism. The Corrmittee was not able to assess 
the safety of stevioside as many of the data referred to inadequately specified materials. 
The results of long-term and reproduction studies as well as metabolism data are required 
on a specified material before a safety assessment can be made by the Corrmittee. 
Thaumatin 
This sweetener is a mixture of closely related sweet proteins extracted from the fruit of 
the West African plant Thaumatococcus danielli. It is me of the sweetest substances 
known, its sweet taste developing slowly but being of long duration. The Corrmittee was 
informed that the whole seed of the fruit has a history of native use in West Africa. The 
15 -main active agents are the proteins thaumatin I and thaumatin II, both of which have a 
relative mass of about 20 000. They are rich in basic amino acids with an isoelectric 
point of about pH 11, but they do not cmtain histidin. Thaumatin is used in food at 
various levels up to about 30 ppm resulting in an estimated daily intake of 1-2 mg per 
person/day. This is very different from the intakes experienced with other intense 
sweeteners. The available studies cover the nature and consumption of the sweetener, the 
nature and sequence of the constituent amino acids, allergenicity, digestibility, 
mutagenicity and the absence of other foreign protein. The existing subchronic feeding 
studies are reassuring regarding the safety of this protein. The question of receptor 
binding and possible endocrine activity was raised. Some reassuring information was 
provided, particularly m the relationship between intact natural protein configuration and 
sweetness; however, some uncertainty remains m the potential for such activity. The 
Committee did not establish an ADI, but considered the substance to be temporarily 
acceptable until the situation has bem clarified. The Committee wishes to review the 
situation within three years. 
Volemitol 
No information m this compound was supplied to the Corrmittee which was therefore unable to 
evaluate its safety. 
Xylitol 
This polyalcohol is a xylopentane-1,2,3,4,5-pentol. 
It occurs in certain fruits and vegetables, and is formed in the body as intermediate in 
the metabolism of carbohydrates as part of the pentose phosphate shunt. 
The Corrmittee reviewed studies m the metabolism, acute and subchronic toxicity, and m 
chronic toxicity in rats and dogs, as well as a three generation reproduction study in 
rats, teratogenicity studies and the results of several in vitro and in vivo mutagenicity 
tests. Extensive human data m the tolerance of orally administered xylitol were also 
reviewed. Xylitol was non-genotoxic. The changes in metabolism and physiology 
associated with large intakes of polyols were also noticed in the long-term studies with 
xylitol. The human data do not suggest any hazard from urinary excretion of oxalate but 
consumption exceeding about 50 g/day leads to diarrhoea. The Corrmittee did not consider 
it appropriate to establish an ADI for this polyol, but considered its use acceptable 
provided the limitations due to its laxative effect were kept in mind. 
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